Effects of Coffee Consumption on Metabolic Markers in Adults With Prediabetes and Obesity
NCT ID: NCT06330727
Last Updated: 2024-03-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
100 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-02-05
Study Completion Date
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Epidemiological studies have shown an inverse association between coffee consumption and risk of type 2 diabetes. However, the randomized controlled trials in prediabetes are limited to evaluate the effects of coffee. The purpose of this study is to investigate the effects of coffee on metabolic factors and inflammation in individuals with prediabetes and obesity. A double-blind, randomized controlled trial is designed to explore the effects of coffee consumption on participants with prediabetes and obesity. A total of 100 eligible participants with prediabetes and obesity will be recruited from the Health Management Center of Nanjing First Hospital. These participants are randomly assigned in a 1:1 ratio to either the coffee capsule group or the control group. The coffee capsule group will be instructed to consume 3.6 g of coffee capsules per day (0.3 g per capsule, 6 capsules per serving, twice a day, once in the morning and once in the middle of the day). The control group will be asked to consume 3.6 g of cornstarch capsules (0.3 g per capsule, 6 capsules per serving, twice a day, once in the morning and once in the middle of the day). 75 g oral glucose tolerance test, 2-week blinded continuous glucose measurement and others will be performed before and after the 3-month intervention. During the three months of intervention, the information on dietary intake, physical activity and sleep of participants will be systematically collected. To comprehensively assess the impact of coffee intake on prediabetes and obesity, we will analyze the effects of coffee capsules on various metabolic and inflammatory markers, including glucose metabolism, lipid profiles, blood pressure, adiponectin, high sensitivity C-reactive protein, interleukin-6, body mass index, body composition, the degree of hepatic steatosis and so on. We will further adjust for potential confounding factors such as lifestyle factors to better understand the underlying biological mechanisms driving this association.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coffee and Metabolic Health Outcomes
NCT01738399
Insulin Resistance
COMPLETED
NA
Experimental Studies of the Effects of Caffeine on Glucose Regulation
NCT00432887
Diabetes Mellitus, Type 2
COMPLETED
EARLY_PHASE1
The Effects of Specialty Coffee on Cognitive Function in People With Type 2 Diabetes
NCT05709847
Type 2 Diabetes
UNKNOWN
NA
Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes
NCT02689765
Insulin Resistance
Glucose Metabolism Disorders
Type 2 Diabetes
+1 more
COMPLETED
PHASE4
Effects of Coffee Roasting on Blood Sugar Levels in Healthy Humans
NCT05119153
Hyperglycemia
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants with both prediabetes and obesity who undergo physical examinations at the Health Management Center of Nanjing First Hospital will be recruited for this study. The details of this study design are as follows:
1\. Inclusion and exclusion criteria for participants. Inclusion criteria are as follows: 1) Age between 18 and 59 years old; 2) Body mass index (BMI) ≥ 28 kg/m2; 3) No consumption of coffee in the past month; 4) Provide written informed consent; 5) Abnormal glucose tolerance, as per the 1999 WHO diagnostic criteria for prediabetes, includes impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or a combination of both, with blood glucose fluctuations within an abnormal range (fasting blood glucose ≥6.1 mmol/L but \<7.0 mmol/L, and/or 2-hour glucose tolerance blood glucose ≥7.8 mmol/L but \<11.1 mmol/L). The exclusion criteria for participants include individuals who 1) have been diagnosed with diabetes or are taking anti-diabetic drugs; 2) have a history of diseases such as cancer, liver and kidney dysfunction, existing cardiovascular and cerebrovascular diseases, and other diseases that may affect glucose and lipid metabolism; 3) self-report gastrointestinal reaction or intolerance to coffee and reject coffee consumption; 4) are pregnant or planning to become pregnant in the near future; 5) are deemed unsuitable to participate in this study by researcher believes that they are not to participate in this study.
2\. Sample size calculation: Based on the estimation of research purpose, research design, expected effect size, and statistical analysis method, the sample size is determined to be 100 cases, including fifty cases in the intervention group and fifty cases in the control group.
3\. Definition of the intervention group and placebo group: the intervention group serves as the coffee capsule group, and will receive 3.6 g of coffee capsules per day (0.3 g/capsule, 6 capsules/time, 2 times/day, once in the morning and once in the middle of the day). The placebo group (control group) is required to consume 3.6 g of cornstarch capsules per day (0.3 g/capsule, 6 capsules/time, 2 times/day, once in the morning and once in the middle of the day).
4\. Follow-up and data collection: this follow-up period will span three months. Before and after the 3-month intervention the participants will partake in:
1. regular assessments. Demographic characteristics and medical information will be collected, including age, gender, occupation, education level, income, medication history (hormones, contraceptives, etc.), and family history of chronic diseases. Besides, using questionnaires, we also collect lifestyle information such as smoking, drinking, diet intake, physical activity, and sleep of participants. Specifically, the Simplified Food Frequency Questionnaire (FFQ25) and 24-hour Diet Record Questionnaire (DR) are employed to assess the dietary intake of participants in the past six months and the previous 24 hours (one day each in the middle of the week and on the weekend), respectively. International Physical Activity Questionnaire (IPAQ) is utilized to assess various aspects of physical activity, including time, frequency, and intensity. The sleep information (sleep time, sleep quality, etc.) is evaluated by Pittsburgh sleep quality index (PSQI).
2. A 75 g oral glucose tolerance test (75 g-OGTT). Blood samples are taken fasting and 30, 120 minutes after the glucose load. Blood samples are analyzed for glucose, insulin, C-peptide, and glucagon.
3. 2-week continuous glucose measurement using blinded continuous glucose monitor/sensor on upper arm.
4. Fasting blood samples: glycated hemoglobin (HbA1c), total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglycerides, high sensitivity C-reactive protein (CRP), interleukin 6 (IL-6).
5. Furthermore, blood pressure, transient hepatic elastography for the assessment of fatty liver degree, body composition analysis, and heart rhythm variation analysis are collected using corresponding instrument and equipment inspection. Additionally, blood, urine, and stool samples will be collected for further analysis.
1\. Inclusion and exclusion criteria for participants. Inclusion criteria are as follows: 1) Age between 18 and 59 years old; 2) Body mass index (BMI) ≥ 28 kg/m2; 3) No consumption of coffee in the past month; 4) Provide written informed consent; 5) Abnormal glucose tolerance, as per the 1999 WHO diagnostic criteria for prediabetes, includes impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or a combination of both, with blood glucose fluctuations within an abnormal range (fasting blood glucose ≥6.1 mmol/L but \<7.0 mmol/L, and/or 2-hour glucose tolerance blood glucose ≥7.8 mmol/L but \<11.1 mmol/L). The exclusion criteria for participants include individuals who 1) have been diagnosed with diabetes or are taking anti-diabetic drugs; 2) have a history of diseases such as cancer, liver and kidney dysfunction, existing cardiovascular and cerebrovascular diseases, and other diseases that may affect glucose and lipid metabolism; 3) self-report gastrointestinal reaction or intolerance to coffee and reject coffee consumption; 4) are pregnant or planning to become pregnant in the near future; 5) are deemed unsuitable to participate in this study by researcher believes that they are not to participate in this study.
2\. Sample size calculation: Based on the estimation of research purpose, research design, expected effect size, and statistical analysis method, the sample size is determined to be 100 cases, including fifty cases in the intervention group and fifty cases in the control group.
3\. Definition of the intervention group and placebo group: the intervention group serves as the coffee capsule group, and will receive 3.6 g of coffee capsules per day (0.3 g/capsule, 6 capsules/time, 2 times/day, once in the morning and once in the middle of the day). The placebo group (control group) is required to consume 3.6 g of cornstarch capsules per day (0.3 g/capsule, 6 capsules/time, 2 times/day, once in the morning and once in the middle of the day).
4\. Follow-up and data collection: this follow-up period will span three months. Before and after the 3-month intervention the participants will partake in:
1. regular assessments. Demographic characteristics and medical information will be collected, including age, gender, occupation, education level, income, medication history (hormones, contraceptives, etc.), and family history of chronic diseases. Besides, using questionnaires, we also collect lifestyle information such as smoking, drinking, diet intake, physical activity, and sleep of participants. Specifically, the Simplified Food Frequency Questionnaire (FFQ25) and 24-hour Diet Record Questionnaire (DR) are employed to assess the dietary intake of participants in the past six months and the previous 24 hours (one day each in the middle of the week and on the weekend), respectively. International Physical Activity Questionnaire (IPAQ) is utilized to assess various aspects of physical activity, including time, frequency, and intensity. The sleep information (sleep time, sleep quality, etc.) is evaluated by Pittsburgh sleep quality index (PSQI).
2. A 75 g oral glucose tolerance test (75 g-OGTT). Blood samples are taken fasting and 30, 120 minutes after the glucose load. Blood samples are analyzed for glucose, insulin, C-peptide, and glucagon.
3. 2-week continuous glucose measurement using blinded continuous glucose monitor/sensor on upper arm.
4. Fasting blood samples: glycated hemoglobin (HbA1c), total cholesterol, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglycerides, high sensitivity C-reactive protein (CRP), interleukin 6 (IL-6).
5. Furthermore, blood pressure, transient hepatic elastography for the assessment of fatty liver degree, body composition analysis, and heart rhythm variation analysis are collected using corresponding instrument and equipment inspection. Additionally, blood, urine, and stool samples will be collected for further analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Prediabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coffee capsule
participants in this arm ingest coffee capsules with 1.8g instant black coffee powder twice daily with breakfast and lunch.
Group Type
ACTIVE_COMPARATOR
Coffee capsule
Intervention Type
DIETARY_SUPPLEMENT
Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
Placebo
participants in this arm consume cornstarch capsules (without coffee) twice daily with breakfast and lunch.
Group Type
PLACEBO_COMPARATOR
Corn starch capsule
Intervention Type
DIETARY_SUPPLEMENT
Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coffee capsule
Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
Intervention Type
DIETARY_SUPPLEMENT
Corn starch capsule
Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
Intervention Type
DIETARY_SUPPLEMENT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
0 sugar 0 fat black coffee, instant black coffee. Product standard code: Q/QC 0001S. Food production license number: SC10644190004159.
Edible corn starch. Product standard code: GB 31637. Food production license number: SC10313102300041.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age between 18 and 59 years old;
2. Diagnosis of Prediabetes according to the WHO criteria (fasting glucose=6.1-6.9 mmol/L and/or 2-hour post-OGTT glucose=7.8- 11.0 mmol/L);
3. Body mass index ( BMI ) ≥ 28kg/m2;
4. No coffee intake in the past month;
5. Provide written informed consent and be willing to participate.
2. Diagnosis of Prediabetes according to the WHO criteria (fasting glucose=6.1-6.9 mmol/L and/or 2-hour post-OGTT glucose=7.8- 11.0 mmol/L);
3. Body mass index ( BMI ) ≥ 28kg/m2;
4. No coffee intake in the past month;
5. Provide written informed consent and be willing to participate.
Exclusion Criteria
1. Patients with diagnosis of diabetes, or taking anti-diabetic medication;
2. Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;
3. Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;
4. Pregnancy, planned pregnancy, or lactation;
5. Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease).
2. Patients with cardiovascular or cerebrovascular diseases, cancer, renal disease, liver disease, other chronic diseases affecting glucose and lipid metabolism, etc;
3. Participants with known hypersensitivity or intolerance to coffee, or unwilling to accept coffee;
4. Pregnancy, planned pregnancy, or lactation;
5. Investigators, for any reason, consider the participants inappropriate for the study (e.g., uncontrolled bipolar disease).
Minimum Eligible Age
18 Years
Maximum Eligible Age
59 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing First Hospital, Nanjing Medical University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jun Wang, M.D.,phD.
Role: PRINCIPAL_INVESTIGATOR
Health Management Center of Nanjing First Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanjing First Hospital
Nanjing, Jiangsu, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care. 2014 Feb;37(2):569-86. doi: 10.2337/dc13-1203.
Reference Type
BACKGROUND
Scheen AJ, Letiexhe MR, Ernest P. [Prevention of type 2 diabetes: lifestyle changes or pharmacological interventions?]. Rev Med Liege. 2003 Apr;58(4):206-10. French.
Reference Type
BACKGROUND
Schulze MB, Hu FB. Primary prevention of diabetes: what can be done and how much can be prevented? Annu Rev Public Health. 2005;26:445-67. doi: 10.1146/annurev.publhealth.26.021304.144532.
Reference Type
BACKGROUND
Magis D, Geronooz I, Scheen AJ. [Smoking, insulin resistance and type 2 diabetes]. Rev Med Liege. 2002 Sep;57(9):575-81. French.
Reference Type
BACKGROUND
Higdon JV, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr. 2006;46(2):101-23. doi: 10.1080/10408390500400009.
Reference Type
BACKGROUND
van Dam RM. Coffee and type 2 diabetes: from beans to beta-cells. Nutr Metab Cardiovasc Dis. 2006 Jan;16(1):69-77. doi: 10.1016/j.numecd.2005.10.003. Epub 2005 Dec 13.
Reference Type
BACKGROUND
Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses. PLoS One. 2018 Mar 20;13(3):e0194127. doi: 10.1371/journal.pone.0194127. eCollection 2018.
Reference Type
BACKGROUND
Kondo Y, Goto A, Noma H, Iso H, Hayashi K, Noda M. Effects of Coffee and Tea Consumption on Glucose Metabolism: A Systematic Review and Network Meta-Analysis. Nutrients. 2018 Dec 27;11(1):48. doi: 10.3390/nu11010048.
Reference Type
BACKGROUND
Bae JM. Coffee consumption and risk of type 2 diabetes mellitus in Asians: A meta-epidemiological study of population-based cohort studies. World J Diabetes. 2021 Jun 15;12(6):908-915. doi: 10.4239/wjd.v12.i6.908.
Reference Type
BACKGROUND
Di Maso M, Boffetta P, Negri E, La Vecchia C, Bravi F. Caffeinated Coffee Consumption and Health Outcomes in the US Population: A Dose-Response Meta-Analysis and Estimation of Disease Cases and Deaths Avoided. Adv Nutr. 2021 Jul 30;12(4):1160-1176. doi: 10.1093/advances/nmaa177.
Reference Type
BACKGROUND
Osama H, Abdelrahman MA, Madney YM, Harb HS, Saeed H, Abdelrahim MEA. Coffee and type 2 diabetes risk: Is the association mediated by adiponectin, leptin, c-reactive protein or Interleukin-6? A systematic review and meta-analysis. Int J Clin Pract. 2021 Jun;75(6):e13983. doi: 10.1111/ijcp.13983. Epub 2021 Jan 21.
Reference Type
BACKGROUND
Shahinfar H, Jayedi A, Khan TA, Shab-Bidar S. Coffee consumption and cardiovascular diseases and mortality in patients with type 2 diabetes: A systematic review and dose-response meta-analysis of cohort studies. Nutr Metab Cardiovasc Dis. 2021 Aug 26;31(9):2526-2538. doi: 10.1016/j.numecd.2021.05.014. Epub 2021 May 24.
Reference Type
BACKGROUND
Carlstrom M, Larsson SC. Coffee consumption and reduced risk of developing type 2 diabetes: a systematic review with meta-analysis. Nutr Rev. 2018 Jun 1;76(6):395-417. doi: 10.1093/nutrit/nuy014.
Reference Type
BACKGROUND
Bhupathiraju SN, Pan A, Manson JE, Willett WC, van Dam RM, Hu FB. Changes in coffee intake and subsequent risk of type 2 diabetes: three large cohorts of US men and women. Diabetologia. 2014 Jul;57(7):1346-54. doi: 10.1007/s00125-014-3235-7. Epub 2014 Apr 26.
Reference Type
BACKGROUND
van Dam RM, Feskens EJ. Coffee consumption and risk of type 2 diabetes mellitus. Lancet. 2002 Nov 9;360(9344):1477-8. doi: 10.1016/S0140-6736(02)11436-X.
Reference Type
BACKGROUND
Bidel S, Silventoinen K, Hu G, Lee DH, Kaprio J, Tuomilehto J. Coffee consumption, serum gamma-glutamyltransferase and risk of type II diabetes. Eur J Clin Nutr. 2008 Feb;62(2):178-85. doi: 10.1038/sj.ejcn.1602712. Epub 2007 Mar 7.
Reference Type
BACKGROUND
Greenberg JA, Boozer CN, Geliebter A. Coffee, diabetes, and weight control. Am J Clin Nutr. 2006 Oct;84(4):682-93. doi: 10.1093/ajcn/84.4.682.
Reference Type
BACKGROUND
Doo T, Morimoto Y, Steinbrecher A, Kolonel LN, Maskarinec G. Coffee intake and risk of type 2 diabetes: the Multiethnic Cohort. Public Health Nutr. 2014 Jun;17(6):1328-36. doi: 10.1017/S1368980013000487. Epub 2013 Feb 27.
Reference Type
BACKGROUND
Greenberg JA, Axen KV, Schnoll R, Boozer CN. Coffee, tea and diabetes: the role of weight loss and caffeine. Int J Obes (Lond). 2005 Sep;29(9):1121-9. doi: 10.1038/sj.ijo.0802999.
Reference Type
BACKGROUND
Iso H, Date C, Wakai K, Fukui M, Tamakoshi A; JACC Study Group. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med. 2006 Apr 18;144(8):554-62. doi: 10.7326/0003-4819-144-8-200604180-00005.
Reference Type
BACKGROUND
Karabegovic I, Portilla-Fernandez E, Li Y, Ma J, Maas SCE, Sun D, Hu EA, Kuhnel B, Zhang Y, Ambatipudi S, Fiorito G, Huang J, Castillo-Fernandez JE, Wiggins KL, de Klein N, Grioni S, Swenson BR, Polidoro S, Treur JL, Cuenin C, Tsai PC, Costeira R, Chajes V, Braun K, Verweij N, Kretschmer A, Franke L, van Meurs JBJ, Uitterlinden AG, de Knegt RJ, Ikram MA, Dehghan A, Peters A, Schottker B, Gharib SA, Sotoodehnia N, Bell JT, Elliott P, Vineis P, Relton C, Herceg Z, Brenner H, Waldenberger M, Rebholz CM, Voortman T, Pan Q, Fornage M, Levy D, Kayser M, Ghanbari M. Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption. Nat Commun. 2021 May 14;12(1):2830. doi: 10.1038/s41467-021-22752-6.
Reference Type
BACKGROUND
Hang D, Kvaerner AS, Ma W, Hu Y, Tabung FK, Nan H, Hu Z, Shen H, Mucci LA, Chan AT, Giovannucci EL, Song M. Coffee consumption and plasma biomarkers of metabolic and inflammatory pathways in US health professionals. Am J Clin Nutr. 2019 Mar 1;109(3):635-647. doi: 10.1093/ajcn/nqy295.
Reference Type
BACKGROUND
Shang F, Li X, Jiang X. Coffee consumption and risk of the metabolic syndrome: A meta-analysis. Diabetes Metab. 2016 Apr;42(2):80-7. doi: 10.1016/j.diabet.2015.09.001. Epub 2015 Oct 1.
Reference Type
BACKGROUND
Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017 Nov 22;359:j5024. doi: 10.1136/bmj.j5024.
Reference Type
BACKGROUND
Grosso G, Godos J, Galvano F, Giovannucci EL. Coffee, Caffeine, and Health Outcomes: An Umbrella Review. Annu Rev Nutr. 2017 Aug 21;37:131-156. doi: 10.1146/annurev-nutr-071816-064941.
Reference Type
BACKGROUND
Pan MH, Tung YC, Yang G, Li S, Ho CT. Molecular mechanisms of the anti-obesity effect of bioactive compounds in tea and coffee. Food Funct. 2016 Nov 9;7(11):4481-4491. doi: 10.1039/c6fo01168c.
Reference Type
BACKGROUND
Martini D, Del Bo' C, Tassotti M, Riso P, Del Rio D, Brighenti F, Porrini M. Coffee Consumption and Oxidative Stress: A Review of Human Intervention Studies. Molecules. 2016 Jul 28;21(8):979. doi: 10.3390/molecules21080979.
Reference Type
BACKGROUND
Shi X, Xue W, Liang S, Zhao J, Zhang X. Acute caffeine ingestion reduces insulin sensitivity in healthy subjects: a systematic review and meta-analysis. Nutr J. 2016 Dec 28;15(1):103. doi: 10.1186/s12937-016-0220-7.
Reference Type
BACKGROUND
Ding M, Satija A, Bhupathiraju SN, Hu Y, Sun Q, Han J, Lopez-Garcia E, Willett W, van Dam RM, Hu FB. Association of Coffee Consumption With Total and Cause-Specific Mortality in 3 Large Prospective Cohorts. Circulation. 2015 Dec 15;132(24):2305-15. doi: 10.1161/CIRCULATIONAHA.115.017341. Epub 2015 Nov 16.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20231109-09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Acute Effects of Coffee on Glucose Metabolism
NCT00950898
COMPLETED
NA
Impact of Alpha-Lipoic Acid Ingestion on Glucose Tolerance in Subjects With Pre-Diabetes
NCT03612037
COMPLETED
NA
Efficacy Assessment of Chinese Herbal Medicine Jiangtang Tiaozhi Recipe Treating Participants With Glucose and Lipid Metabolism Disturbances
NCT04623567
UNKNOWN
PHASE1/PHASE2
Intervention Effects of Optimized Carbohydrate Diet in Patients With Type 2 Diabetes
NCT06936657
NOT_YET_RECRUITING
NA
Effect of Fiber on Glycemic Index
NCT02615327
COMPLETED
NA
Effects on Metabolism and Cognitive Functions of a Commonly Used Commercial Food Supplement
NCT02392819
COMPLETED
NA
Effect of Nutritional Supplements on Clinical Outcomes in Patients With Prediabetes and Obesity
NCT05273840
UNKNOWN
NA
Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Gestational Diabetic Patients
NCT01912170
UNKNOWN
NA
Effect of Probiotics on Pre-diabetes and Diabetes in China
NCT03377946
UNKNOWN
NA
To Evaluate the Impact of Consumption of a Bioactive Compound on Fasting Blood Glucose Levels in Asian Indians With Pre-diabetes
NCT06417840
RECRUITING
NA
Post-prandial Glycemic Response to Fiber in Healthy Adults
NCT03252704
COMPLETED
NA
Efficacy of Diacylglycerol Oil on Metabolic Risk Factors in Prediabetes
NCT07289880
NOT_YET_RECRUITING
NA
Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance
NCT03658564
UNKNOWN
NA
A Trial to Study the Effect of Vitamin D Supplementation on Glucose and Insulin Metabolism in Centrally Obese Men
NCT00347542
COMPLETED
NA
Taurine Supplementation on Cognitive Function in Patients With Diabetes
NCT03410173
UNKNOWN
NA
Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes
NCT03219411
COMPLETED
PHASE2
The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes
NCT02929901
COMPLETED
PHASE2/PHASE3
Coffee Roasting and Glucose Tolerance
NCT02417519
COMPLETED
NA
Effect of Three Fibres on Glycaemic and Insulinaemic Responses in Healthy Adult Volunteers
NCT02701270
COMPLETED
NA
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
NCT06492655
NOT_YET_RECRUITING
PHASE1
Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients
NCT01857167
COMPLETED
NA
Blood Sugar Take Care and Glucose Metabolism
NCT01554020
WITHDRAWN
PHASE2
Prevention of Type 2 Diabetes Mellitus by Changes in Diet
NCT02250066
COMPLETED
NA
Type 2 Diabetes Intervention by Gut Microbiota-directed Diet -a Open Labelled RCT
NCT05541237
UNKNOWN
NA
Effect of Medicago Sativa on Oral Glucose Tolerance in Healthy Adults
NCT03714438
COMPLETED
PHASE2